https://www.thebodypro.com/tag/id-week

IDWeek

The Latest

pill bottles on page full of data

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.

a bottle of Truvada on top of Truvada pills at pharmacy

Gilead Announced It Will Donate 2.4 Million Bottles of Truvada for PrEP. Here's How It Will Work.

Gilead Sciences is working with the federal government to roll out its pre-exposure prophylaxis (PrEP) donation program. Here, we detail what we know so far about how this will be implemented.

PrEP Posters

Black Women in Atlanta Need More PrEP Access. Researchers and Advocates Are Working to Make This a Reality.

While most pre-exposure prophylaxis (PrEP) campaigns focus on gay and bisexual men, Fulton County Board of Health officials and advocates look for solutions to get PrEP to black women.

doctor talking and smiling to male patient

The HIV Workforce Is in Trouble. Here Are Three Solutions to Address the Shortage of Providers.

If everyone living with HIV gets into care, do we have enough providers to support them? HIV doctors are proposing policy changes to address the workforce shortage.

Various Road Closed signs

Test-and-Treat for Hepatitis C: What Are the Obstacles?

A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.

grindr screens

Grindr Users Take PrEP More and Have Lower HIV Rates, but Have Higher Rate of STIs Than Men Not on the App

Gay and bisexual men who used Grindr were having more sex acts associated with increased risk, but were more likely to use PrEP or be open to it, which translated to lower HIV incidence.

Doctors from HIVMA and IDSA on Capitol Hill

Doctors Meet With Congressional Staff to Push for 'Ending the HIV Epidemic' Budget

At IDWeek in Washington, D.C., leading infectious disease doctors and researchers met with U.S. Congress leadership to discuss HIV prevention, treatment, and care policy.

Washington DC at sunset, including Washington Monument

IDWeek 2019: What to Expect at This Year's Conference

We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.

Promo Image

What Is the State of the Art in HIV Treatment and Prevention?

With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...